Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/s

**What Happened:** This case involved a patent dispute between two pharmaceutical companies - Caraco Pharmaceutical Laboratories and Novo Nordisk. Caraco challenged Novo Nordisk's patents, claiming they were invalid because Novo Nordisk had acted dishonestly when applying for the patents. Specifically, Caraco argued that Novo Nordisk failed to tell the Patent Office about existing similar inventions that should have been considered during the patent review process. **What the Court Decided:** The Supreme Court sided with Caraco, ruling that Novo Nordisk's patents were unenforceable. The Court found that Novo Nordisk had engaged in "inequitable conduct" by deliberately hiding important information about prior inventions from the Patent Office when seeking their patents. This dishonest behavior made their patents invalid. **Why This Matters for Workers:** This decision helps ensure fair competition in the pharmaceutical industry, which can lead to more affordable medications for workers and their families. When companies cannot maintain patents through dishonest means, it opens the door for generic drug manufacturers to create cheaper alternatives. The ruling also reinforces that all companies, regardless of size, must follow honest practices when dealing with government agencies.